|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
|
US7892793B2
(en)
*
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
|
CA2528012C
(en)
*
|
2003-06-02 |
2015-11-24 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
|
US7750144B2
(en)
*
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
CA2527958C
(en)
*
|
2003-06-02 |
2014-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of rnai
|
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
|
WO2005027980A1
(en)
*
|
2003-09-12 |
2005-03-31 |
University Of Massachusetts |
Rna interference for the treatment of gain-of-function disorders
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
US20070265220A1
(en)
*
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
EP2239328A3
(en)
|
2005-08-18 |
2011-01-05 |
Alnylam Pharmaceuticals Inc. |
Methods and compositions for treating neurological disease
|
|
JP2010500011A
(ja)
|
2006-08-08 |
2010-01-07 |
ガンサー ハートマン |
５’リン酸オリゴヌクレオチドの構造および使用
|
|
WO2008143774A2
(en)
*
|
2007-05-01 |
2008-11-27 |
University Of Massachusetts |
Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
|
|
US9738680B2
(en)
|
2008-05-21 |
2017-08-22 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5′ triphosphate oligonucleotide with blunt end and uses thereof
|
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
|
US9433684B2
(en)
|
2008-08-19 |
2016-09-06 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
|
US8225729B2
(en)
*
|
2008-12-16 |
2012-07-24 |
Kimberly-Clark Worldwide, Inc. |
Three-dimensional wiping substrate and method therefor
|
|
US11414664B2
(en)
|
2008-12-18 |
2022-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
KR20110110776A
(ko)
|
2008-12-18 |
2011-10-07 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
US20120022142A1
(en)
*
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
EP2756845B1
(en)
*
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
|
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
|
|
WO2011005363A2
(en)
*
|
2009-05-18 |
2011-01-13 |
Ensysce Biosciences, Inc. |
Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
|
|
WO2010141933A1
(en)
*
|
2009-06-05 |
2010-12-09 |
Dicerna Pharmaceuticals, Inc. |
Specific inhibition of gene expression by nucleic acid containing a dicer substrate
|
|
WO2010144058A1
(en)
|
2009-06-10 |
2010-12-16 |
Temasek Life Sciences Laboratory Limited |
Virus induced gene silencing (vigs) for functional analysis of genes in cotton.
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
CA2781896C
(en)
*
|
2009-12-09 |
2021-03-30 |
Nitto Denko Corporation |
Modulation of hsp47 expression
|
|
WO2011072292A2
(en)
*
|
2009-12-11 |
2011-06-16 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of rna and rna derivatives
|
|
JP5257796B2
(ja)
*
|
2009-12-28 |
2013-08-07 |
株式会社村田製作所 |
固体電解コンデンサ素子及びその製造方法
|
|
DK2591105T3
(en)
|
2010-07-06 |
2017-07-31 |
Dicerna Pharmaceuticals Inc |
METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA
|
|
AU2011276363A1
(en)
|
2010-07-06 |
2013-01-10 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2857499A1
(en)
*
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
|
WO2012056440A1
(en)
*
|
2010-10-28 |
2012-05-03 |
Nanodoc Ltd. |
COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
|
|
EP2681314B1
(en)
|
2011-03-03 |
2017-11-01 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
DK2718442T3
(en)
|
2011-06-10 |
2017-08-14 |
Temasek Life Sciences Laboratory Ltd |
GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR SUBPHYLA OF PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA
|
|
WO2012173994A2
(en)
*
|
2011-06-15 |
2012-12-20 |
Dicerna Pharmaceuticals, Inc. |
Phase changing formulations of nucleic acid payloads
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
AU2012325997C1
(en)
|
2011-10-18 |
2018-07-05 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
|
US9796974B2
(en)
|
2011-11-18 |
2017-10-24 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
US9352042B2
(en)
|
2012-02-24 |
2016-05-31 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
EP2839007B1
(en)
|
2012-04-19 |
2017-12-27 |
Temasek Life Sciences Laboratory Limited |
Methods for increasing cotton fiber length
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
US9850486B2
(en)
|
2012-12-14 |
2017-12-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA
|
|
CA3120574A1
(en)
|
2013-03-14 |
2014-09-25 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
EP3932947A1
(en)
|
2013-03-14 |
2022-01-05 |
Translate Bio MA, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CA2916499A1
(en)
|
2013-07-03 |
2015-01-08 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
SI3581654T1
(sl)
|
2013-12-27 |
2021-08-31 |
Dicerna Pharmaceuticals, Inc. |
Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
|
|
US10351854B2
(en)
|
2014-10-10 |
2019-07-16 |
Dicerna Pharmaceuticals, Inc. |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
|
WO2016064347A1
(en)
|
2014-10-22 |
2016-04-28 |
Temasek Life Sciences Laboratory Limited |
Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
|
|
EP3865576A1
(en)
|
2014-12-15 |
2021-08-18 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
US10689647B2
(en)
|
2015-05-08 |
2020-06-23 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
|
|
WO2017004357A1
(en)
*
|
2015-07-02 |
2017-01-05 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
WO2018045317A1
(en)
|
2016-09-02 |
2018-03-08 |
Dicerna Pharmaceuticals, Inc. |
4'-phosphate analogs and oligonucleotides comprising the same
|
|
JP7208911B2
(ja)
*
|
2017-10-11 |
2023-01-19 |
日東電工株式会社 |
核酸分子発現の調節
|
|
HRP20231063T1
(hr)
|
2017-10-13 |
2023-12-22 |
Novo Nordisk Health Care Ag |
Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha
|
|
EP3684377B1
(en)
|
2017-10-20 |
2022-12-07 |
Dicerna Pharmaceuticals, Inc. |
Methods for treating hepatitis b infection
|
|
AU2019205904A1
(en)
|
2018-01-05 |
2020-06-18 |
Dicerna Pharmaceuticals, Inc. |
Reducing beta-catenin and IDO expression to potentiate immunotherapy
|
|
EP3710588A4
(en)
|
2018-01-16 |
2021-08-18 |
Dicerna Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION
|
|
BR112021000538A2
(pt)
|
2018-07-13 |
2021-04-06 |
F. Hoffmann-La Roche Ag |
Oligonucleotídeos para modular a expressão de rtel1
|
|
WO2020051231A1
(en)
|
2018-09-04 |
2020-03-12 |
H. Lee Moffitt Cancer Center & Research Institute Inc. |
Use of delta-tocotrienol for treating cancer
|
|
US11452738B2
(en)
|
2019-01-04 |
2022-09-27 |
Empirico Inc. |
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
|
|
WO2020167593A1
(en)
|
2019-02-12 |
2020-08-20 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for inhibiting expression of cyp27a1
|
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
AU2020252560A1
(en)
|
2019-04-04 |
2021-10-28 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
WO2020226960A1
(en)
|
2019-05-03 |
2020-11-12 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
MX2022002533A
(es)
|
2019-08-30 |
2022-06-02 |
Dicerna Pharmaceuticals Inc |
Ácidos nucleicos modificados con ligandos 2', síntesis de estos y compuestos intermedios de estos.
|
|
US20220389430A1
(en)
|
2019-10-02 |
2022-12-08 |
Dicema Pharmaceuticals, Inc. |
Chemical modifications of small interfering rna with minimal fluorine content
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
EP4081217A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
|
|
CA3172117A1
(en)
|
2020-03-18 |
2021-09-23 |
Bob D. Brown |
Compositions and methods for inhibiting angptl3 expression
|
|
JP2023537499A
(ja)
|
2020-08-04 |
2023-09-01 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
オリゴヌクレオチドの全身送達
|
|
MX2023001450A
(es)
|
2020-08-04 |
2023-04-14 |
Dicerna Pharmaceuticals Inc |
Composiciones y metodos para la inhibicion de la expresion de plp1.
|
|
TW202221120A
(zh)
|
2020-08-04 |
2022-06-01 |
美商黛瑟納製藥公司 |
用於治療代謝症候群之組成物及方法
|
|
KR20250077604A
(ko)
|
2020-08-05 |
2025-05-30 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
|
JP2023536999A
(ja)
|
2020-08-05 |
2023-08-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎患者のオリゴヌクレオチド処置
|
|
IL305634A
(en)
|
2021-03-05 |
2023-11-01 |
Dicerna Pharmaceuticals Inc |
Rnai conjugates and uses thereof
|
|
MX2023012048A
(es)
|
2021-04-12 |
2023-10-23 |
Boehringer Ingelheim Int |
Composiciones y metodos para inhibir cetohexoquinasa (khk).
|
|
KR20230171431A
(ko)
|
2021-04-14 |
2023-12-20 |
다이서나 파마수이티컬, 인크. |
Pnpla3 발현을 조절하기 위한 조성물 및 방법
|
|
IL307154A
(en)
|
2021-04-19 |
2023-11-01 |
Novo Nordisk As |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|
|
US11655473B2
(en)
|
2021-05-28 |
2023-05-23 |
Novo Nordisk A/S |
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
|
|
KR20240046843A
(ko)
|
2021-08-25 |
2024-04-11 |
노보 노르디스크 에이/에스 |
알파-1 항트립신 발현을 억제하기 위한 조성물 및 방법
|
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
|
JP7877458B2
(ja)
|
2021-12-01 |
2026-06-22 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ａｐｏｃ３発現を調節するための組成物及び方法
|
|
JP2025512445A
(ja)
|
2022-04-15 |
2025-04-17 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ｓｃａｐ活性を調節するための組成物及び方法
|
|
CA3247389A1
(en)
|
2022-05-12 |
2023-11-16 |
Dicerna Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MAPT
|
|
JP2025518507A
(ja)
|
2022-05-13 |
2025-06-17 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
Ｓｎｃａの発現を阻害するための組成物及び方法
|
|
TWI868755B
(zh)
|
2022-06-24 |
2025-01-01 |
丹麥商諾佛 儂迪克股份有限公司 |
抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法
|
|
US20260049309A1
(en)
|
2022-08-15 |
2026-02-19 |
Novo Nordisk A/S |
Regulation of activity of rnai molecules
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
TW202511486A
(zh)
|
2023-07-28 |
2025-03-16 |
美商黛瑟納製藥公司 |
用於程式化死亡配體受體（ｐｄ－ｌ１）表現之組成物和方法
|
|
WO2025054459A1
(en)
|
2023-09-08 |
2025-03-13 |
Dicerna Pharmaceuticals, Inc. |
Rnai oligonucleotide conjugates
|
|
AU2024349303A1
(en)
|
2023-09-25 |
2026-04-23 |
Acurna Ltd. |
Modified nucleoside compound, and oligonucleotide prepared therefrom
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026041910A2
(en)
|
2024-08-21 |
2026-02-26 |
Novo Nordisk A/S |
Compositions and methods for inhibiting xdh expression
|
|
WO2026083241A1
(en)
|
2024-10-15 |
2026-04-23 |
Genevant Sciences Gmbh |
Ionizable lipids comprising n,n-substituted hydroxylamine esters
|
|
WO2026162643A1
(en)
|
2025-01-31 |
2026-08-06 |
Novo Nordisk A/S |
Nucleic acid constructs for inhibiting gys2 expression
|